NRx Announces Publication of Initial Findings of BriLife® Vaccine-produced Antibodies Against Omicron Variant
- Thursday, January 27, 2022, 7:07
- Finance
- Add a comment
RADNOR, Pa., Jan. 27, 2022 /PRNewswire/ — NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage, biopharmaceutical company has received scientific evidence from the Israel Institute for Biological Research (IIBR) that the BriLife® vaccine may produce effective levels of neutralizing…
About the Author
adminasapcorp has written 39670 stories on this site.